TTOO News and Press, T2 Biosystems Inc. From 04/18/21

Will These Penny Stocks Grow As The Biotech Sector Pushes Up? With penny stocks, high volatility can often be used as an asset. While buying penny stocks is not for everyone, the potential with stocks under $5 can be high. On the other hand, some investors will shy away from penny...

T2 Biosystems (TTOO) has filed for a mixed shelf offering of up to $150M.The filing does not necessarily indicate that a sale has begun, or will occur in the future.T2 shares are down 1.9% to $1.59 in after-hours trading. For further details see: T2 Biosystems f...

Biotech Penny Stocks For Your Q2 Watch List Biotech penny stocks have been some of the most consistently watched names over the past year. The pandemic definitely helped shed light on this industry. It also saw millions of new traders flock to buy the next big breakout stock working...

All proceeds from the book sale will be donated to Sepsis Alliance and Donate Life America LEXINGTON, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced ...

T2 Biosystems (TTOO) Vice President and General Counsel Michael Gibbs has sold ~8.8K of company shares at an average price of $1.56 per share.The transaction valued at $13.7K lowers his stake to ~73.3K shares. This is the second sell transaction by Mr. Gibbs after he sold ~7.3K shares in Febr...

Gainers: Second Sight Medical Products EYES +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences EVFM -34%, T2 Biosystems (...

T2 Biosystems, Inc. (TTOO) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group John Sperzel - President and CEO John Sprague - Chief Financial Officer Conference Call Participants Westley Dupray - SVB Leerink Max M...

T2 Biosystems (TTOO) shares rise nearly 15% in after market trading as the company posted fourth-quarter results that were largely in-line with Wall Street estimates, and provided financial forecast for the year.Total revenue for the fourth quarter was $7.8M, an increase of 154% com...

T2 Biosystems (TTOO): Q4 GAAP EPS of -$0.07 in-line.Revenue of $7.78M (+151.0% Y/Y) misses by $0.02M.2021 Financial OutlookThe Company expects full year 2021 total revenue to be between $24.0 million and $26.0 million ($32.59M consensus), including product revenue between $16.0 million and $1...

LEXINGTON, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights Achieve...